Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5196557
Max Phase: Preclinical
Molecular Formula: C62H90N12O16S
Molecular Weight: 1291.54
Associated Items:
ID: ALA5196557
Max Phase: Preclinical
Molecular Formula: C62H90N12O16S
Molecular Weight: 1291.54
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCOC)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C
Standard InChI: InChI=1S/C62H90N12O16S/c1-9-35(6)52(74-54(81)41(63)28-36-13-11-10-12-14-36)62(89)72-48(32-50(78)79)60(87)68-44(27-33(2)3)56(83)70-47(31-49(64)77)59(86)69-45(29-37-15-19-39(75)20-16-37)58(85)67-43(23-25-90-7)55(82)73-51(34(4)5)61(88)71-46(30-38-17-21-40(76)22-18-38)57(84)66-42(53(65)80)24-26-91-8/h10-22,33-35,41-48,51-52,75-76H,9,23-32,63H2,1-8H3,(H2,64,77)(H2,65,80)(H,66,84)(H,67,85)(H,68,87)(H,69,86)(H,70,83)(H,71,88)(H,72,89)(H,73,82)(H,74,81)(H,78,79)/t35-,41-,42-,43-,44-,45-,46-,47-,48-,51-,52-/m0/s1
Standard InChI Key: ZUOLDIVPCPAUOQ-BZWGMARWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1291.54 | Molecular Weight (Monoisotopic): 1290.6318 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Yoshida J, Takayama K, Kawada M.. (2022) Short peptides derived from hGAPDH exhibit anti-cancer activity., 71 [PMID:35964520] [10.1016/j.bmc.2022.116953] |
Source(1):